Test results
March 2025–Labcorp tests results
p-tau181 (0.85, High, Reference Interval 0.00-0.18)
Notes from the internet:
Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of Alzheimer's disease (AD) because they are more available and cost-effective than cerebrospinal fluid (CSF) or neuroimaging. Therefore, we aimed to evaluate whether phosphorylated tau181 (p-tau181) in plasma could be an accurate AD predictor.
Conclusions: Plasma p-tau181 level is related to multiple AD-associated cognitive domains and AD-related CSF biomarkers at the clinical stages of AD. Moreover, plasma p-tau181 level is related to the change rates of cognitive decline and hippocampal atrophy. Thus, this study confirms the utility of plasma p-tau181 as a non-invasive biomarker for early detection and prediction of AD.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8452983/
p-tau217 (1.81, High, reference interval 0.00-0.97)
Notes from the internet:
Useful for evaluation of individuals, aged 50 years and older, presenting with cognitive impairment who are being assessed for Alzheimer disease and other causes of cognitive decline
This test is not intended as a screening test for Alzheimer disease in asymptomatic individuals.
https://www.mayocliniclabs.com/test-catalog/overview/621635
Comments
Post a Comment